|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Portal vein thrombosis with protein C-S deficiency in a noncirrhotic patient显示文摘There are several conditions that can lead to portal vein thrombosis(PVT), including including infection, malignancies, and coagulation disorders. Anew condition of interest is protein C and S deficiencies, associated with hypercoagulation and recurrent venous thromboembolism. We report the case of a non-cirrhotic 63-year-old male diagnosed with acute superior mesenteric vein thrombosis and PVT and combined deficiencies in proteins C and S, recanalized by short-term low molecular heparin plus oral warfarin therapy. | Gustavo A Rodríguez-Leal Segundo Morán Roberto Corona-Cedillo Rocío Brom-Valladares | 2014 | World Journal of Hepatology2014，6，7： | 10 |
| 2 | Differential colorectal carcinogenesis:Molecular basis and clinical relevance显示文摘Colorectal cancer(CCR) is one of the most frequent cancers in developed countries.It poses a major public health problem and there is renewed interest in understanding the basic principles of the molecular biology of colorectal cancer.It has been established that sporadic CCRs can arise from at least two different carcinogenic pathways.The traditional pathway,also called the suppressor or chromosomal instability pathway,follows the Fearon and Vogelstein model and shows mutation in classical oncogenes and tumour suppressor genes,such as K-ras,adenomatous polyposis coli,deleted in colorectal cancer,or p53.Alterations in the Wnt pathway are also very common in this type of tumour.The second main colorectal carcinogenesis pathway is the mutator pathway.This pathway is present in nearly 15% of all cases of sporadic colorectal cancer.It is characterized by the presence of mutations in the microsatellite sequences caused by a defect in the DNA mismatch repair genes,mostly in hMLH1 or hMSH2.These two pathways have clear molecular differences,which will be reviewed in this article,but they also present distinct histopathological features.More strikingly,their clinical behaviours are completely different,having the 'mutator' tumours a better outcome than the 'suppressor' tumours. | Alberto Morán Paloma Ortega Carmen de Juan Tamara Fernández-Marcelo Cristina Frías Andrés Sánchez-Pernaute Antonio José Torres Eduardo Díaz-Rubio Pilar Iniesta Manuel Benito | 2010 | World Journal of Gastrointestinal Oncology2010，2，3： | 5 |
| 3 | Inflammatory bowel disease: An increased risk factor for neurologic complications显示文摘Only a very few systematic studies have investigated the frequency of neurologic disorders in patients with Crohn's disease(CD) and ulcerative colitis(UC), which are the two main types of inflammatory bowel disease(IBD). Results have been inconsistent and variable, owing to differences in case-finding methods and evaluated outcomes in different studies. The most frequent neurologic manifestations reported in CD and UC populations are cerebrovascular disease(with either arterial or venous events), demyelinating central nervous system disease, and peripheral neuropathy(whether axonal or demyelinating); however, the literature describes numerous nervous system disorders as being associated with IBD. The pathogenesis of nervous system tissue involvement in IBD has yet to be elucidated, although it seems to be related to immune mechanisms or prothrombotic states. The recently-introduced tumor necrosis factor(TNF) inhibitors have proven successful in controlling moderate to severe IBD activity. However, severe neurologic disorders associated with TNF inhibitors have been reported, which therefore raises concerns regarding the effect of anti-TNF-α antibodies on the nervous system. Although neurological involvement associated with IBD is rarely reported, gastroenterologists should be aware of the neurologic manifestations of IBD in order to provide early treatment, which is crucial for preventing major neurologic morbidity. | Germán Morís | 2014 | World Journal of Gastroenterology2014，20，5： | 3 |
| 4 | Extracellular vesicles in liver disease and beyond显示文摘Extracellular vesicles(EVs) are membrane-derived vesicles which can be released by different cell types, including hepatocytes, hepatic stellate cells and immune cells in normal and pathological conditions. EVs carry lipids, proteins, coding and non-coding RNAs and mitochondrial DNA causing modifications on the recipient cells. These vesicles are considered potential biomarkers and therapeutic agents for human diagnostic and prognostic due to their function as intercellular mediators of cell-cell communication within the liver and between other organs. However, the development and optimization of methods for EVs isolation is required to characterize their biological functions as well as their potential as a treatment option in the clinic. Nevertheless, many questions remain unanswered related to the function of EVs under physiological and pathological conditions. In the current editorial, the results obtained in different studies that investigated the role of intrahepatic EVs during liver diseases, including drug-induced liver injury, non-alcoholic fatty liver, nonalcoholic steatohepatitis, alcoholic liver disease and hepatocellular carcinoma and extrahepatic EVs in remote organs during pathological events such as pulmonary disease, cardiovascular diseases, neurodegenerative disorders e.g., Alzheimer's disease, Parkinson's disease and multiple sclerosis as well as in immunopathological processes, are discussed. Although much light needs to be shed on the mechanisms of EVs, these membranederived vesicles represent both a novel promising diagnostic, and a therapeutic tool for clinical use that we emphasize in the current editorial. | Laura Morán Francisco Javier Cubero | 2018 | World Journal of Gastroenterology2018，24，40： | 3 |
| 5 | Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats显示文摘 | Leonor Rivera Rocío Morón Antonio Zarzuelo Milagros Galisteo | 2008 | Biochemical Pharmacology2008，，6： | 2 |
| 6 | Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab显示文摘 | C.Taxonera J.Estellés I.Fernández‐Blanco O.Merino I.Marín‐Jiménez M.Barreiro‐de Acosta C.Saro V.García‐Sánchez E.Gento G.Bastida J. P.Gisbert I.Vera P.Martinez‐Montiel S.Garcia‐Morán M. C.Sánchez J. L.Mendoza | 2011 | Alimentary Pharmacology & Therapeutics2011，，3： | 2 |
| 7 | Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding显示文摘 | Merlob P Mor N Litwin A | 1992 | Ann Pharmacother1992，26，12： | 1 |
| 8 | Organometallics显示文摘 | Cuadrado I Morán M Casado C M | 1996 | 15:5 2781996，15，： | 1 |
| 9 | Stiffness of systemic arteries in appropriate and small - for - gestational-age newborn infants 显示文摘 | Mor IA Uchida N Inomo A | 2012 | Pediatrics2012，118，3： | 1 |
| 10 | The karnofsky performance status scale: an examination of its reliability and validity in a research setting 显示文摘 | Mor V Laliberte L Morris J N | 1984 | Cancer1984，53，9： | 1 |
| 11 | Phase Istudy of concurrent chemoradiation with pemetrexed andcisplatin followed by consolidation pemetrexed for patientswith unresectable stage III non-small cell lung cancer显示文摘 | Cardenal F Arnaiz MD Mor 6 n T | 2011 | Lung cancer2011，74，1： | 1 |
| 12 | Microbes Central to Human Reproduction显示文摘 | Gregor Reid Patrizia Brigidi Jeremy P. Burton Nikhat Contractor Sylvia Duncan Emilie Fargier Colin Hill Sarah Lebeer Rocio Martín Andrew J. McBain Gil Mor Catherine O’Neill Juan Miguel Rodríguez Jonathan Swann Saskia Hemert Juliett Ansell | 2015 | Am J Reprod Immunol2015，，1： | 1 |
| 13 | UV-absorbing plastic sheets protect crops from insect pests and from virus diseases vectored by insects显示文摘 | ANTIGNUS Y MOR N BEN JOSEPH R | 1996 | Environ Entomol1996，25，： | 1 |
| 14 | Amino acid-based surfactants显示文摘 | María Rosa Infante Lourdes Pérez Aurora Pinazo Pere Clapés María Carmen Morán Marta Angelet María Teresa García María Pilar Vinardell | 2004 | Comptes rendus - Chimie2004，，6： | 1 |
| 15 | Mitochondrial respiratory chain dysfunction: Implications in neurodegeneration显示文摘 | María Morán David Moreno-Lastres Lorena Marín-Buera Joaquín Arenas Miguel A. Martín Cristina Ugalde | 2012 | Free Radical Biology and Medicine2012，，3： | 1 |
| 16 | ImmuKnow: a new parameter in immune monitoring of pediatric liver transplantation recipients 显示文摘 | Israeli M Klein T Sredni B Avitzur Y Mor E Bar Nathen N | 2008 | Liver Transpl2008，14，： | 1 |
| 17 | Identification of Smad7,a TGF beta-inducible antagonist of TGF-beta signalling显示文摘 | Nakao A Afrakhte M Morén A | 1997 | Nature1997，389，6651： | 1 |
| 18 | Proteome profile changes during mouse testis development显示文摘 | María Paz Matías Morín Jesús del Mazo | 2006 | Comparative Biochemistry and Physiology - Part D: Genomics and Proteomics2006，，4： | 1 |
| 19 | Reduced energy consumption during low strength domestic wastewater treatment in a semi-pilot tubular microbial electrolysis cell显示文摘 | L. Gil-Carrera A. Escapa R. Moreno A. Morán | 2013 | Journal of Environmental Management2013，，： | 1 |
| 20 | Combined UV-Vis absorbance and fluorescence properties of extractedhumic substances-like for characterization of composting evolution of do-mestic solid wastes显示文摘 | MORN VIEYRA F E PALAZZI V I SANCHEZ DE PINTO M I | 2009 | Geoderma2009，151，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员